• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TP53基因缺陷型金黄叙利亚仓鼠的癌症谱:李-弗劳梅尼综合征的一种新模型。

Cancer spectrum in TP53-deficient golden Syrian hamsters: A new model for Li-Fraumeni syndrome.

作者信息

Miao Jinxin, Li Rong, Wettere Arnaud J Van, Guo Haoran, Tabaran Alexandru-Flaviu, O'Sullivan M Gerald, Carlson Timothy, Scott Patricia M, Chen Kuisheng, Gao Dongling, Li Huixiang, Wang Yaohe, Wang Zhongde, Cormier Robert T

机构信息

Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA.

Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, Academy of Medical Sciences, Zhengzhou University, Henan, China.

出版信息

J Carcinog. 2021 Oct 7;20:18. doi: 10.4103/jcar.jcar_18_21. eCollection 2021.

DOI:10.4103/jcar.jcar_18_21
PMID:34729050
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8531574/
Abstract

BACKGROUND

The tumor suppressor gene is the most commonly mutated gene in human cancers. Humans who inherit mutant alleles develop a wide range of early onset cancers, a disorder called Li-Fraumeni Syndrome (LFS). -deficient mice recapitulate most but not all of the cancer phenotypes observed in -deficient human cancers, indicating that new animal models may complement current mouse models and better inform on human disease development.

MATERIALS AND METHODS

The recent application of CRISPR/Cas9 genetic engineering technology has permitted the emergence of golden Syrian hamsters as genetic models for wide range of diseases, including cancer. Here, the first cancer phenotype of knockout golden Syrian hamsters is described.

RESULTS

Hamsters that are homozygous for mutations become moribund on average ~ 139 days of age, while hamsters that are heterozygous become moribund at ~ 286 days. homozygous knockout hamsters develop a wide range of cancers, often synchronous and metastatic to multiple tissues, including lymphomas, several sarcomas, especially hemangiosarcomas, myeloid leukemias and several carcinomas. heterozygous mutants develop a more restricted tumor spectrum, primarily lymphomas.

CONCLUSIONS

Overall, hamsters may provide insights into how deficiency leads to cancer in humans and can become a new model to test novel therapies.

摘要

背景

肿瘤抑制基因是人类癌症中最常发生突变的基因。携带突变等位基因的人会患多种早发性癌症,这种疾病称为李-佛美尼综合征(LFS)。基因缺陷的小鼠重现了基因缺陷人类癌症中观察到的大部分而非全部癌症表型,这表明新的动物模型可能补充当前的小鼠模型,并更好地为人类疾病发展提供信息。

材料与方法

CRISPR/Cas9基因工程技术的最新应用使得金黄地鼠成为包括癌症在内的多种疾病的遗传模型。在此,描述了基因敲除金黄地鼠的首个癌症表型。

结果

基因纯合突变的仓鼠平均在约139日龄时濒死,而杂合仓鼠在约286日龄时濒死。基因纯合敲除仓鼠会患多种癌症,通常是同步发生且转移至多个组织,包括淋巴瘤、几种肉瘤,尤其是血管肉瘤、髓系白血病和几种癌。基因杂合突变体的肿瘤谱较窄,主要是淋巴瘤。

结论

总体而言,仓鼠可能有助于深入了解基因缺陷如何导致人类患癌,并可成为测试新疗法的新模型。

相似文献

1
Cancer spectrum in TP53-deficient golden Syrian hamsters: A new model for Li-Fraumeni syndrome.TP53基因缺陷型金黄叙利亚仓鼠的癌症谱:李-弗劳梅尼综合征的一种新模型。
J Carcinog. 2021 Oct 7;20:18. doi: 10.4103/jcar.jcar_18_21. eCollection 2021.
2
A novel cancer syndrome caused by -deficiency in the golden Syrian hamster.金黄叙利亚仓鼠中因β-缺乏引起的一种新型癌症综合征。
J Carcinog. 2018 Oct 10;17:6. doi: 10.4103/jcar.JCar_5_18. eCollection 2018.
3
Golden Syrian Hamster Models for Cancer Research.癌症研究用金黄叙利亚仓鼠模型。
Cells. 2022 Aug 3;11(15):2395. doi: 10.3390/cells11152395.
4
Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.巴西个体中 TP53 p.R337H 突变的 Li-Fraumeni 综合征/Li-Fraumeni 样综合征的临床谱。
J Steroid Biochem Mol Biol. 2019 Jun;190:250-255. doi: 10.1016/j.jsbmb.2019.04.011. Epub 2019 Apr 8.
5
Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.巴西南部儿童癌症患者中李-佛美尼综合征和李-佛美尼样综合征。
Cancer. 2013 Dec 15;119(24):4341-9. doi: 10.1002/cncr.28346. Epub 2013 Oct 7.
6
TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.李-佛美尼综合征及类李-佛美尼综合征家族中的TP53和CDKN1A突变分析
Fam Cancer. 2017 Apr;16(2):243-248. doi: 10.1007/s10689-016-9935-z.
7
A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.在西班牙一系列疑似李-弗劳梅尼综合征的家族中鉴定出一种新型的TP53生殖系框内缺失。
Fam Cancer. 2017 Oct;16(4):567-575. doi: 10.1007/s10689-017-9990-0.
8
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.180 个疑似李-佛美尼综合征家族的 TP53 种系突变检测:不同家族表型中癌症的突变检出率和相对频率。
J Med Genet. 2010 Jun;47(6):421-8. doi: 10.1136/jmg.2009.073429.
9
Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer predisposition syndrome.李-弗劳梅尼癌症易感性综合征表型异质性和早现现象的全基因组测序分析
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15497-501. doi: 10.1073/pnas.1417322111. Epub 2014 Oct 13.
10
Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.《结肠癌家族登记处早发性结直肠癌患者的胚系 TP53 突变》
JAMA Oncol. 2015 May;1(2):214-21. doi: 10.1001/jamaoncol.2015.0197.

引用本文的文献

1
CRISPR technology in human diseases.用于人类疾病治疗的CRISPR技术。
MedComm (2020). 2024 Jul 29;5(8):e672. doi: 10.1002/mco2.672. eCollection 2024 Aug.
2
Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer.整合单细胞和批量 RNA 测序以预测前列腺癌的预后和免疫治疗反应。
Sci Rep. 2023 Sep 20;13(1):15597. doi: 10.1038/s41598-023-42858-9.
3
Identification of optimal reference genes in golden Syrian hamster with ethanol- and palmitoleic acid-induced acute pancreatitis using quantitative real-time polymerase chain reaction.

本文引用的文献

1
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.一种单价减毒 YF17D 载体 SARS-CoV-2 疫苗候选物。
Nature. 2021 Feb;590(7845):320-325. doi: 10.1038/s41586-020-3035-9. Epub 2020 Dec 1.
2
Targeting TP53 Mutations in Myelodysplastic Syndromes.针对骨髓增生异常综合征中的 TP53 突变。
Hematol Oncol Clin North Am. 2020 Apr;34(2):421-440. doi: 10.1016/j.hoc.2019.11.004. Epub 2019 Dec 12.
3
Mutant p53 on the Path to Metastasis.突变型p53在转移进程中的作用
采用实时定量聚合酶链反应鉴定乙醇和棕榈油酸诱导的金黄地鼠急性胰腺炎的最佳参考基因。
Animal Model Exp Med. 2023 Dec;6(6):609-618. doi: 10.1002/ame2.12321. Epub 2023 May 18.
4
Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy.叙利亚仓鼠作为癌症免疫疗法评价的理想动物模型。
Front Immunol. 2023 Feb 27;14:1126969. doi: 10.3389/fimmu.2023.1126969. eCollection 2023.
5
Characterization of SHARPIN knockout Syrian hamsters developed using CRISPR/Cas9 system.利用 CRISPR/Cas9 系统构建的 SHARPIN 基因敲除叙利亚仓鼠的鉴定。
Animal Model Exp Med. 2023 Oct;6(5):489-498. doi: 10.1002/ame2.12265. Epub 2022 Sep 12.
6
Golden Syrian Hamster Models for Cancer Research.癌症研究用金黄叙利亚仓鼠模型。
Cells. 2022 Aug 3;11(15):2395. doi: 10.3390/cells11152395.
Trends Cancer. 2020 Jan;6(1):62-73. doi: 10.1016/j.trecan.2019.11.004. Epub 2019 Dec 16.
4
The Diverse Functions of Mutant 53, Its Family Members and Isoforms in Cancer.突变体 53 及其家族成员和同工型在癌症中的多种功能。
Int J Mol Sci. 2019 Dec 7;20(24):6188. doi: 10.3390/ijms20246188.
5
The role of TP53 in acute myeloid leukemia: Challenges and opportunities.TP53 在急性髓系白血病中的作用:挑战与机遇。
Genes Chromosomes Cancer. 2019 Dec;58(12):875-888. doi: 10.1002/gcc.22796. Epub 2019 Sep 3.
6
Current status and new treatment approaches in TP53 mutated AML.TP53 基因突变型 AML 的现状和新的治疗方法。
Best Pract Res Clin Haematol. 2019 Jun;32(2):134-144. doi: 10.1016/j.beha.2019.05.004. Epub 2019 May 11.
7
Adrenocortical carcinoma - towards genomics guided clinical care.肾上腺皮质癌——迈向基于基因组学的临床治疗。
Nat Rev Endocrinol. 2019 Sep;15(9):548-560. doi: 10.1038/s41574-019-0221-7.
8
TP53 and therapy-related myeloid neoplasms.TP53 与治疗相关的髓系肿瘤。
Best Pract Res Clin Haematol. 2019 Mar;32(1):98-103. doi: 10.1016/j.beha.2019.02.009. Epub 2019 Feb 19.
9
Hematologic malignancies and Li-Fraumeni syndrome.血液系统恶性肿瘤与李-弗劳梅尼综合征。
Cold Spring Harb Mol Case Stud. 2019 Feb 1;5(1). doi: 10.1101/mcs.a003210. Print 2019 Feb.
10
Mutant p53 in cancer therapy-the barrier or the path.癌症治疗中的突变型 p53:障碍还是途径。
J Mol Cell Biol. 2019 Apr 1;11(4):293-305. doi: 10.1093/jmcb/mjy072.